Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of SAR408701 versus docetaxel in previously treated CEACAM5-positive metastatic nonsquamous non-small cell lung cancer
MOH_2020-06-10_009022Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Feb 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC) comparing SAR408701 with docetaxel (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Feb 2020; status: recruiting.
02
Drugs
tusamitamab ravtansinedocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on MOH_2020-06-10_009022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-06-10_009022.